TCP
JAZZ icon

Tourbillon Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tourbillon Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50,000
Closed -$7.26M – 75
2017
Q1 		$7.26M Buy
+50,000
New +$6.51M 0.19% 52

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Tourbillon Capital Partners's JAZZ Position: Q2 2017 in Review

Tourbillon Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2017, closing a stake of 192,407 shares — an estimated $27.9M sold.

Tourbillon Capital Partners first reported a position in JAZZ in Q3 2016 and held it in 3 quarters. The position peaked at $90.2M in Q4 2016. 319 funds tracked by Wall St. Rank hold JAZZ as of Q2 2017.

  • Tourbillon Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Tourbillon Capital Partners sold 192,407 Jazz Pharmaceuticals shares in Q2 2017, an estimated $27.9M.
  • Tourbillon Capital Partners first reported a position in Jazz Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Tourbillon Capital Partners's Jazz Pharmaceuticals position peaked at $90.2M in Q4 2016.
  • 319 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2017.

Based on Tourbillon Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.